Table 2.
Novel targeted therapies: risk of invasive fungal infections.
| Target | Agents | Risk for IFI | Prophylaxis |
|---|---|---|---|
| BTK | Ibrutinib Acalabrutinib Zanubrutinib |
High |
● Consider antifungal prophylaxis if other risk factors present. ● PJP prophylaxis if receiving corticosteroid therapy 1. |
| CD52 | Alemtuzumab | High | ● PJP prophylaxis recommended |
| PI3K | Idelalisib Copanlisib Duvelisib |
Moderate/High | ● PJP prophylaxis recommended |
| CD19/CD3 | Blinatumomab | Moderate | ● PJP prophylaxis recommended |
| BCL-2 | Venetoclax | Moderate | ● PJP prophylaxis if receiving corticosteroid therapy 1. |
| CD20 | Rituximab Ofatumumab Obinutuzumab |
Moderate/Low | ● PJP prophylaxis if receiving corticosteroid therapy 1. ● Consider for RCHOP14. |
| JAK | Ruxolitinib | Moderate/Low | ● PJP prophylaxis if receiving corticosteroid therapy 1. |
| SLAMF7 | Elotuzumab | Low | Minimal additional risk added |
| CD38 | Daratumumab | Low | Minimal additional risk added |
| FLT3 | Midostaurin Gilterinib |
Low | Minimal additional risk added 2 |
1 Prednisone equivalent ≥20 mg/day for >4 weeks. 2 Given with standard induction therapy during which there is a recommendation for anti-mold prophylaxis.